脾多肽注射液联合TACE治疗晚期肝癌临床观察
|
摘要
目的近年来肝癌发病率不断升高,针对晚期肝癌患者治疗的研究不断增多。本研究分析脾多肽注射液联合肝动脉插管化疗栓塞术(transcatheter arterial chemoembolization,TACE)对晚期肝癌临床效果及对患者肝功能影响。方法在2015-01-01-2017-12-31安阳市肿瘤医院介入科收治的晚期肝癌患者中,按照匹配的方法分别选择对照组54例,观察组54例进行分析。对照组进行常规TACE治疗,观察组采用脾多肽注射液联合TACE治疗,对比两组治疗效果、肝功能指标及肿瘤标志物水平。结果观察组治疗总有效率为96.3%,高于对照组的81.48%,χ~2=6.004,P=0.014。治疗后,观察组谷丙转氨酶(alanine aminotransferase,ALT)水平为(75.13±7.58)IU/L,高于对照组的(73.01±8.33)IU/L,t=8.188,P=0.039;观察组谷草转氨酶(aspartate aminotransferase,AST)水平为(92.04±9.31)IU/L,高于对照组的(85.33±8.14)IU/L,t=8.352,P=0.038;观察组白蛋白(albumin,ALB)水平为(31.17±5.11)g/L,低于对照组的(33.46±4.39)g/L,t=9.014,P=0.035;观察组甲胎蛋白(alpha fetoprotein,AFP)水平为(159.42±14.38)μg/L,低于对照组的(233.01±21.57)μg/L,t=10.846,P=0.029;观察组癌胚抗原(carcinoembryonic antigen,CEA)水平为(22.59±2.37)μg/L,低于对照组(25.18±3.26)μg/L,t=7.251,P=0.044;观察组糖类抗原(carbohydrate antigen19-9,CA19-9)水平为(135.74±12.88)ng/mL,低于对照组的(141.31±15.39)ng/mL,t=8.667,P=0.037。结论脾多肽注射液联合TACE可有效提高晚期肝癌患者临床治疗效果,改善患者肝功能指标,并降低肿瘤标志物水平。
OBJECTIVE In recent years,the incidence of liver cancer has been increasing,and research on the treatment of patients with advanced liver cancer has been increasing.This study aims to analyze the clinical effect of spleen polypeptide injection combined with transcatheter arterial chemoembolization(TACE) on advanced liver cancer and its effect on liver function.METHODS A total of 108 patients with advanced liver cancer admitted to the Department of Interventional of Anyang Cancer Hospital from January 2015 to December 2017 were divided into control group(54 cases) and observation group(54 cases) according to matching method.The control group received routine TACE treatment,the observation group was treated with spleen polypeptide injection combined with TACE.The therapeutic effect,liver function index and tumor marker level were compared between the two groups.RESULTS The total effective rate of the observation group was 96.3%,which was higher than that of the control group(81.48%),χ~2=6.004,P=0.014.After treatment,the level of alanine aminotransferase(ALT) in the observation group was(75.13±7.58)IU/L,which was higher than that of the control group(73.01±8.33)IU/L,t=8.188,P=0.039.The level of aspartate aminotransferase(AST) in the observation group was(92.04±9.31)IU/L,which was higher than that of the control group(85.33±8.14)IU/L,t=8.352,P=0.038.The level of albumin(ALB) in the observation group was(31.17±5.11)g/L,which was lower than that of the control group(33.46±4.39)g/L,t=9.014,P=0.035.The level of alpha fetoprotein(AFP)in the observation group was(159.42±14.38)μg/L,which was lower than that of the control group(233.01±21.57)μg/L,t=10.846,P=0.029.The level of carcinoembryonic antigen(CEA) in the observation group was(22.59±2.37)μg/L,which was lower than that of the control group(25.18±3.26)μg/L,t=7.251,P=0.044.The level of carbohydrate antigen 19-9(CA19-9) in the observation group was(135.74±12.88)ng/ml,which was lower than that of the control group(141.31±15.39)ng/ml,t=8.667,P=0.037.CONCLUSIONS Spleen polypeptide injection combined with TACE can effectively improve the clinical treatment effect of patients with advanced liver cancer,improve the liver function of patients and reduce the level of tumor markers.
OBJECTIVE In recent years,the incidence of liver cancer has been increasing,and research on the treatment of patients with advanced liver cancer has been increasing.This study aims to analyze the clinical effect of spleen polypeptide injection combined with transcatheter arterial chemoembolization(TACE) on advanced liver cancer and its effect on liver function.METHODS A total of 108 patients with advanced liver cancer admitted to the Department of Interventional of Anyang Cancer Hospital from January 2015 to December 2017 were divided into control group(54 cases) and observation group(54 cases) according to matching method.The control group received routine TACE treatment,the observation group was treated with spleen polypeptide injection combined with TACE.The therapeutic effect,liver function index and tumor marker level were compared between the two groups.RESULTS The total effective rate of the observation group was 96.3%,which was higher than that of the control group(81.48%),χ~2=6.004,P=0.014.After treatment,the level of alanine aminotransferase(ALT) in the observation group was(75.13±7.58)IU/L,which was higher than that of the control group(73.01±8.33)IU/L,t=8.188,P=0.039.The level of aspartate aminotransferase(AST) in the observation group was(92.04±9.31)IU/L,which was higher than that of the control group(85.33±8.14)IU/L,t=8.352,P=0.038.The level of albumin(ALB) in the observation group was(31.17±5.11)g/L,which was lower than that of the control group(33.46±4.39)g/L,t=9.014,P=0.035.The level of alpha fetoprotein(AFP)in the observation group was(159.42±14.38)μg/L,which was lower than that of the control group(233.01±21.57)μg/L,t=10.846,P=0.029.The level of carcinoembryonic antigen(CEA) in the observation group was(22.59±2.37)μg/L,which was lower than that of the control group(25.18±3.26)μg/L,t=7.251,P=0.044.The level of carbohydrate antigen 19-9(CA19-9) in the observation group was(135.74±12.88)ng/ml,which was lower than that of the control group(141.31±15.39)ng/ml,t=8.667,P=0.037.CONCLUSIONS Spleen polypeptide injection combined with TACE can effectively improve the clinical treatment effect of patients with advanced liver cancer,improve the liver function of patients and reduce the level of tumor markers.
引文
[1]周福平,杨喜晶,王真,等.脾多肽注射液联合经导管肝动脉化疗栓塞治疗中晚期原发性肝癌[J].第二军医大学学报,2017,38(3):379-382.
[2]徐兰英,杨国春,王艳丽,等.脾多肽注射液对原发性肝癌患者超声学改变及AFP水平的影响[J].现代生物医学进展,2017,17(18):3574-3578.
[3]丛文铭.原发性肝癌规范化病理诊断方案专家共识[J].肝脏,2011,16(3):244-246.
[4]Koneru M,Purdon TJ,Spriggs D,et al.IL-12secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo[J].Oncoimmunology,2015,4(3):e994446.
[5]张素珍,杨牡丹,刘俊.紫杉醇加奈达铂方案联合脾多肽注射液治疗晚期食管癌临床观察[J].中国药物与临床,2015,15(5):700-702.
[6]王连祥.脾多肽注射液联合化疗治疗晚期卵巢癌的临床疗效观察[J].山西医药杂志,2015,44(16):1921-1923.
[7]韩华,魏强,邱刚,等.脾多肽注射液对宫颈癌新辅助化疗患者免疫功能影响及临床疗效观察[J].河北医科大学学报,2016,37(12):1424-1427.
[8]武晓红,张丽姣,苏文.脾多肽注射液联合TC方案治疗卵巢癌的临床观察[J].中国药物与临床,2016,16(2):252-254.
[9]宁宇.恩替卡韦联合康艾注射液对中晚期肝癌患者肝功能改善作用及抗病毒疗效分析[J].现代中西医结合杂志,2017,26(18):1991-1993.
[10]苏文忠.脾多肽联合化疗治疗晚期非小细胞肺癌临床疗效观察[J].山西医药杂志,2015,44(24):2940-2942.
[11]Théate I,van Baren N,Pilotte L,et al.Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1protein in normal and tumoral human tissues[J].Cancer Immunol Res,2015,3(2):161-172.
[12]苏俊孟,郭晖,夏飞,等.脾多肽对急性肺损伤大鼠TLR9信号相关因子的影响[J].贵州医科大学学报,2017,42(3):296-299.
[13]吕天石,邹英华,王健,等.经肝动脉化疗栓塞术联合射频消融治疗原发性肝癌的现状[J].临床肝胆病杂志,2016,32(1):49-55.
[14]武中林,李智岗,吴晓云,等.经导管肝动脉栓塞与肝动脉灌注化疗栓塞在原发性肝癌介入治疗中的远期疗效比较[J].中国全科医学,2016,19(11):1292-1296.
[15]李成学,杨凯,张红.经肝动脉化疗栓塞术联合全身化疗治疗乳腺癌肝转移的效果及安全性[J].国际医药卫生导报,2016,22(23):3609-3611.
[2]徐兰英,杨国春,王艳丽,等.脾多肽注射液对原发性肝癌患者超声学改变及AFP水平的影响[J].现代生物医学进展,2017,17(18):3574-3578.
[3]丛文铭.原发性肝癌规范化病理诊断方案专家共识[J].肝脏,2011,16(3):244-246.
[4]Koneru M,Purdon TJ,Spriggs D,et al.IL-12secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo[J].Oncoimmunology,2015,4(3):e994446.
[5]张素珍,杨牡丹,刘俊.紫杉醇加奈达铂方案联合脾多肽注射液治疗晚期食管癌临床观察[J].中国药物与临床,2015,15(5):700-702.
[6]王连祥.脾多肽注射液联合化疗治疗晚期卵巢癌的临床疗效观察[J].山西医药杂志,2015,44(16):1921-1923.
[7]韩华,魏强,邱刚,等.脾多肽注射液对宫颈癌新辅助化疗患者免疫功能影响及临床疗效观察[J].河北医科大学学报,2016,37(12):1424-1427.
[8]武晓红,张丽姣,苏文.脾多肽注射液联合TC方案治疗卵巢癌的临床观察[J].中国药物与临床,2016,16(2):252-254.
[9]宁宇.恩替卡韦联合康艾注射液对中晚期肝癌患者肝功能改善作用及抗病毒疗效分析[J].现代中西医结合杂志,2017,26(18):1991-1993.
[10]苏文忠.脾多肽联合化疗治疗晚期非小细胞肺癌临床疗效观察[J].山西医药杂志,2015,44(24):2940-2942.
[11]Théate I,van Baren N,Pilotte L,et al.Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1protein in normal and tumoral human tissues[J].Cancer Immunol Res,2015,3(2):161-172.
[12]苏俊孟,郭晖,夏飞,等.脾多肽对急性肺损伤大鼠TLR9信号相关因子的影响[J].贵州医科大学学报,2017,42(3):296-299.
[13]吕天石,邹英华,王健,等.经肝动脉化疗栓塞术联合射频消融治疗原发性肝癌的现状[J].临床肝胆病杂志,2016,32(1):49-55.
[14]武中林,李智岗,吴晓云,等.经导管肝动脉栓塞与肝动脉灌注化疗栓塞在原发性肝癌介入治疗中的远期疗效比较[J].中国全科医学,2016,19(11):1292-1296.
[15]李成学,杨凯,张红.经肝动脉化疗栓塞术联合全身化疗治疗乳腺癌肝转移的效果及安全性[J].国际医药卫生导报,2016,22(23):3609-3611.